Time to Reconsider Evidence for Anaemia Treatment (TREAT) = Essential Safety Arguments (ESA)

Nephrology Dialysis Transplantation

Volumn 25, Issue 6, 2010, Pages 1734-1737

  Goldsmith, David ^a   Covic, Adrian ^b  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b Hospital of Medicine and Pharmacy   (Romania)

Author keywords

[No Author keywords available]

Indexed keywords

FERRIC CARBOXYMALTOSE; HEMOGLOBIN; IRON DERIVATIVE; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; UNCLASSIFIED DRUG;

ANEMIA; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; DATA ANALYSIS; DRUG EFFECT; DRUG SAFETY; HUMAN; IRON DEFICIENCY; MALIGNANT NEOPLASTIC DISEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; NOTE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; STROKE; THROMBOSIS; TREATMENT OUTCOME;

ANEMIA; CLINICAL TRIALS AS TOPIC; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; ERYTHROPOIETIN; EVIDENCE-BASED MEDICINE; HEMATINICS; HEMOGLOBINS; HUMANS; RENAL INSUFFICIENCY, CHRONIC; SAFETY;

EID: 77952305393     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfq099     Document Type: Note

References (23)

1. Pfeffer M, Burdmann EA, Cooper DE et al. A trial of darbepoetin-alfa in type 2 diabetes and chronic kidney disease. N Engl J Med 2009; 361: 1-14
2. Muntner P, He J, Astor BC, Folsom AR, Coresh J. Traditional and nontraditional risk factors predict coronary heart disease in chronic kidney disease: results from the atherosclerosis risk in communities study. J Am Soc Nephrol 2005; 16: 529-538
3. Singh AK, Szczech L, Tang KL et al. CHOIR Investigators. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 2006; 355: 2085-2098
4. Drüeke TB, Locatelli F, Clyne N et al. CREATE Investigators. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 2006; 355: 2071-2084
5. Ritz E, Rychlik I, Locatelli F, Halimi S. End-stage renal failure in type 2 diabetes: a medical catastrophe of worldwide dimensions. American Journal of Kidney Diseases 1999; 34: 795-808
6. Strippoli GF, Manno C, Schena FP, Craig JC. Haemoglobin and hae-matocrit targets for the anaemia of chronic renal disease. Cochrane Database Syst Rev CD003967 2003
7. Phrommintikul A, Haas SJ, Elsik M, Krum H. Mortality and target haemoglobin concentrations in anaemic patients with chronic kidney disease treated with erythropoietin: a meta-analysis. Lancet 2007; 369: 381-388
8. Locatelli F, Pisoni RL, Combe C et al. Anemia in haemodialysis patients of five European countries: association with morbidity and mortality in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrol Dial Transpl 2004; 19: 121-132 (Pubitemid 38072623)
9. National Kidney Foundation. DOQI Clinical Practice Guidelines for the treatment of anemia of chronic renal failure. Am J Kidney Dis 1997; 30: S192-S240
10. Besarab A, Bolton WK, Browne JK et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 1998; 339: 584-590
11. Ehrenreich H, Weissenborn K, Prange H et al. EPO Stroke Trial Group. Recombinant human erythropoietin in the treatment of acute ischemic stroke. Stroke 2009; 40: e647-e656
12. Hadland BK, Longmore GD. Erythroid-stimulating agents in cancer therapy\potential dangers and biologic mechanisms. J Clin Oncol 2009; 27: 4217-4226
13. Levin A. Understanding recent haemoglobin trials in CKD: methods and lesson learned from CREATE and CHOIR. Nephrol Dial Transplant 2007; 22: 309-312
14. Gaede P, Lund-Andersen H, Parving HH, Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 2008; 358: 580-591
15. Anker SD, Colet JC, Filippatos G et al. Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med 2009; 361: 1-13
16. Foley RN, Curtis BM, Parfrey PS. Erythropoietin therapy, hemoglobin targets and quality of life in healthy hemodialysis patients: a randomized trial. Clin J Am Soc Nephrol 2009; 4: 726-733
17. Covic A, Seica A, Gusbeth-Tatomir P, Goldsmith D. Hemoglobin normalization trials in chronic kidney disease: what should we learn about quality of life as an end point? J Nephrol 2008; 21: 478-484
18. Parfrey PS, Foley RN, Wittreich BH, Sullivan DJ, Zagari MJ, Frei D. Double-blind comparison of full and partial anemia correction in incident hemodialysis patients without symptomatic heart disease. J Am Soc Nephrol 2005; 16: 2180-2189
19. Eckardt KU, Scherhag A, Macdougall IC et al. Left ventricular geometry predicts cardiovascular outcomes associated with anemia correction in CKD. J Am Soc Nephro 2009
20. Roger SD, McMahon LP, Clarkson A et al. Effects of early and late intervention with epoetin alpha on left ventricular mass among patients with chronic kidney disease (stage 3 or 4): results of a randomized clinical trial. J Am Soc Nephrol 2004; 15: 148-156
21. Levin A, Djurdjev O, Thompson C et al. Canadian randomized trial of hemoglobin maintenance to prevent or delay left ventricular mass growth in patients with CKD. Am J Kidney Dis 2005; 46: 799-811
22. Chan CT, Liu PP, Arab S, Jamal N, Messner HA. Nocturnal hemodi-alysis improves erythropoietin responsiveness and growth of haematopoietic stem cells. J Am Soc Nephrol 2009; 20: 665-671
23. Szczech LA, Barnhart HX, Sapp S. A secondary analysis of the CHOIR trial shows that comorbid conditions differentially affect outcomes during anemia treatment. Kidney Int 2009